• Updated results from the BCMA/CD19 dual-targeted GC012F, including longer-term follow-up and three additional patients, presented at the International Myeloma Society Annual Meeting
  • 100% (19/19) patients achieved minimal residual disease negative stringent complete response (MRD- sCR)

SAN DIEGO, CA, USA and SUZHOU, China and SHANGHAI, China I September 27, 2023 I Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today presented longer-term follow-up data from an ongoing Phase 1 investigator-initiated trial (IIT) evaluating GC012F, a CD19 and B-cell maturation antigen (BCMA) dual-targeted autologous CAR-T therapeutic candidate, as a frontline treatment for patients with transplant-eligible, high-risk, newly diagnosed multiple myeloma (NDMM). The abstract (P-136) was presented as a poster at the 20th International Myeloma Society (IMS) Annual Meeting in Athens, Greece.

GC012F demonstrated a 100% overall response rate (ORR) and a 100% MRD- sCR rate among 19 transplant-eligible, high-risk NDMM patients as of the data cutoff date of August 1, 2023. The data include longer-term follow-up from the initial 16 patients, for whom early results were presented at the 2022 American Society for Hematology (ASH) Annual Meeting, plus three additional patients enrolled and treated. The data also showed that GC012F was well-tolerated with no new safety signals observed in this frontline application of CAR-T therapy.

“Patients with high-risk NDMM, including those who are transplant-eligible, typically face suboptimal outcomes with the current standard of care. Innovation is imperative to address the challenges faced by this group of hard-to-treat patients,” said Dr. Wendy Li, Chief Medical Officer at Gracell. “MRD- sCR is the deepest response possible in the treatment of multiple myeloma patients. We are delighted to report that in this study, all 19 NDMM patients treated by GC012F achieved MRD- sCR with favorable safety. This stands as a testament to the tremendous potential of CAR-T therapy, our pioneering BCMA/CD19 dual-targeting approach, and the enhanced T cell fitness enabled by FasTCAR manufacturing technology.”

In the ongoing single-arm, open label, Phase 1 IIT, patients with NDMM were enrolled and treated with GC012F at three target dose levels. All patients had one or more high-risk features, of which 89% were classified as Stage II or III based on the Revised International Staging System (R-ISS) and 63% had extramedullary plasmacytoma.

As of the data cutoff date of August 1, 2023, with a median follow-up of 15.3 months (range: 3.1-24.5 months), the 19 evaluable patients achieved strong response rates following GC012F infusion:

  • 100% (19/19) ORR;
  • 100% (19/19) sCR;
  • 100% (19/19) of patients achieved minimal residual disease (MRD) negativity, assessed by Euroflow with the sensitivity of 10-6;
  • Median duration of response (DOR) was not reached.

GC012F continued to show a favorable safety profile in the longer-term follow-up with no new safety findings:

  • Only low-grade cytokine release syndrome (CRS) was reported; among the six patients with Grade 1 or 2 CRS, most cases were Grade 1 (5/19, 26%) with only one case of Grade 2 (1/19, 5%);
  • No CRS of any grade occurred in the remaining 68% (13/19) of patients;
  • No immune effector cell-associated toxicity (ICANS) of any grade occurred.

Additional information about the poster and the IMS Annual Meeting is available on the IMS website.

About GC012F
GC012F is Gracell’s FasTCAR-enabled BCMA/CD19 dual-targeting autologous CAR-T cell therapy, which aims to transform cancer and autoimmune disease treatment by driving fast, deep and durable responses with improved safety profile. GC012F is currently being evaluated in clinical studies in multiple hematological cancers as well as autoimmune diseases, and has demonstrated a consistently strong efficacy and safety profile. Gracell has initiated a Phase 1b/2 trial evaluating GC012F for the treatment of relapsed/refractory multiple myeloma in the United States and a Phase 1/2 clinical trial in China is to be commenced imminently. Gracell has also launched an IIT evaluating GC012F for the treatment of refractory systemic lupus erythematosus (rSLE).

About Gracell
Gracell Biotechnologies Inc. (“Gracell”) is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies for the treatment of cancers and autoimmune diseases. Leveraging its innovative FasTCAR and TruUCAR technology platforms and SMART CAR™ technology module, Gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional CAR-T therapies, including lengthy manufacturing time, suboptimal cell quality, high therapy cost, and lack of effective CAR-T therapies for solid tumors and autoimmune diseases. The lead candidate BCMA/CD19 dual-targeting FasTCAR-T GC012F is currently being evaluated in clinical studies for the treatment of multiple myeloma, B-NHL and systemic lupus erythematosus (SLE). For more information on Gracell, please visit www.gracellbio.com. Follow @GracellBio on LinkedIn.

SOURCE: Gracell Biotechnologies